发明授权
US08455445B2 Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
有权
抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法
- 专利标题： Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
- 专利标题（中）： 抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法
-
申请号： US13037092申请日： 2011-02-28
-
公开(公告)号： US08455445B2公开(公告)日： 2013-06-04
- 发明人: Jeffrey L. Browning , Christopher D. Benjamin , Paula S. Hochman
- 申请人： Jeffrey L. Browning , Christopher D. Benjamin , Paula S. Hochman
- 申请人地址： US MA Cambridge
- 专利权人： Biogen Idec MA Inc.
- 当前专利权人： Biogen Idec MA Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： Nelson Mullins Riley & Scarborough LLP
- 代理商 Debra J. Milasincic, Esq.
- 主分类号： A61K38/16
- IPC分类号： A61K38/16 ; A61P19/02 ; C07K19/00 ; C07K14/715
摘要：
This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
公开/授权文献
信息查询
IPC分类:
